In a small, investigator-initiated phase 2 study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed notable activity in pre-treated patients with a difficult-to-treat form of endometrial cancer.
Novel combination therapy shows promise in difficult-to-treat endometrial cancer, study finds
- Thread starter Educator
- Start date